We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Robbins Arroyo LLP: Acquisition of DARA BioSciences, Inc. (DARA) by Midatech Pharma Plc (MTPH) May Not Be in Shareholders' Best Interests PR Newswire SAN DIEGO and RALEIGH, N.C., June 25, 2015...
Lifshitz & Miller Law Firm Announces Investigation of Bio-Reference Laboratories, Inc., DARA BioSciences, Inc., Dealertrack Technologies, Inc., Geeknet, Inc., HCC Insurance Holdings, Inc...
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of DARA BioSciences, Inc. And Encourages Investors To Contact The Firm For Additional Information PR...
Ryan & Maniskas, LLP Investigation of DARA BioSciences, Inc. PR Newswire WAYNE, Pa., June 11, 2015 WAYNE, Pa., June 11, 2015 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating...
DARA BIOSCIENCES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire WILMINGTON, Del., June 10, 2015 WILMINGTON, Del., June 10, 2015 /PRNewswire/...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased DARA BioSciences, Inc. stock prior to June 4, 2015. You are hereby...
http://tickerreport.com/banking-finance/470808/dara-biosciences-now-covered-by-analysts-at-hc-wainright-dara/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN
DARA BioSciences Announces Leadership Transition Current President and COO Christopher G. Clement Named CEO; David J. Drutz, MD Transitions to Executive Chairman and Retains CMO Role; Haywood D...
DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma Second Orphan Drug Designation Received in 2014 for Key Development Asset RALEIGH...
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions